Selectivity of antimuscarinic compounds for muscarinic receptors of human brain and heart.
Article Details
- CitationCopy to clipboard
Larson EW, Pfenning MA, Richelson E
Selectivity of antimuscarinic compounds for muscarinic receptors of human brain and heart.
Psychopharmacology (Berl). 1991;103(2):162-5.
- PubMed ID
- 2027917 [ View in PubMed]
- Abstract
Seven antimuscarinic compounds, used mostly for the treatment of extrapyramidal problems, were tested in vitro in radioligand binding assays for evidence of selectivity for two different pharmacological subtypes of the human muscarinic receptor, M1, a predominant form in brain, and M2, a predominant form in heart. Although biperiden, scopolamine, procyclidine, and benztropine showed significant selectivity in the in vitro assays, it is likely that in clinical practice biperiden would be the drug of choice to avoid any antimuscarinic effects on the heart.
DrugBank Data that Cites this Article
- Drug Targets
Drug Target Kind Organism Pharmacological Action Actions Procyclidine Muscarinic acetylcholine receptor M1 Protein Humans YesAntagonistDetails Procyclidine Muscarinic acetylcholine receptor M2 Protein Humans YesAntagonistDetails